After going it alone, Vivus finally open to Big Pharma sales partnership

Carly Helfand Vivus' announcement that the company is looking to partner with Big Pharma for marketing help to get its new weight-loss drug, Qsymia, off the ground apparently encouraged ...

Arena shares sink after biotech withdraws marketing app for obesity drug in Europe

Ryan McBride Arena Pharmaceuticals ($ ARNA) pulled the plug on its application for approval of the obesity drug Belviq with European regulators, another blow to the commercial and ...

New Shire CEO Ornskov shakes up company after seizing the reins

John Carroll Flemming Ornskov Shire’s ($ SHPG) new CEO wasted no time in putting his stamp on the company’s global operations. In his first quarterly report this ...

Biotech Symphogen tacks on $53.7M to big venture round after Merck Serono deal

Ryan McBride Symphogen has replenished its coffers with €41 million ($ 53.7 million) as the Danish biotech makes progress with next-generation antibody drugs for treating cancer. ...

Allergan slams brakes on two key PhIIIs after data disappoints

John Carroll Allergan has slammed the brakes on two planned late-stage studies of a pair of key therapeutics in its pipeline, saying that investigators have to go back to the mid-stage ...

Aveo shares plunge after FDA raises fears of tivozanib rejection

John Carroll   Regulators at the FDA have weighed the data for Aveo's tivozanib, raising a simple question that could prove vexing for the biotech: Should another clinical ...

NIH stops HIV vaccine trial after immunizations fail

Emily Mullin The federal government has put the brakes on the largest and most advanced study of a vaccine against HIV infection after an independent data and safety monitoring board ...

Gilead keeps lead in hep C race after rivals post key trial results

Ryan McBride After delivering data from multiple rounds of trials on all-oral combos against hepatitis C, pharma runners appear to be making progress with new therapies that could ...

U.K. goes after GSK for decade-old pay-for-delay deal

Eric Palmer Pay-for-delay deals are disliked by regulators on both sides of the Atlantic. A month after the U.S. Supreme Court heard arguments on the practices, regulators in the U.K. ...

Johnson & Johnson cashes out on Elan shares after failed Alzheimer’s trials

Ryan McBride Johnson & Johnson ($ JNJ) has sold 82 million Elan shares ($ ELN) for $ 11.25 per share as part of Elan's $ 1 billion stock buyback plan, providing J&J's ...
Page 13 of 13« First...910111213
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS